Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02228525
Recruitment Status : Active, not recruiting
First Posted : August 29, 2014
Last Update Posted : September 5, 2019
Sponsor:
Collaborators:
M.D. Anderson Cancer Center
Columbia University
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020